N/A N=302 Exercise as a Treatment for Substance Use Disorders Protocol
Stimulant Abuse and Dependence
Primary: Percent Days Abstinent — 90.8; 91.6; 75.5; 77.2 Percentage of Days — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
Epilepsy
Primary: Number Of Participants Who Experienced Severe OLE-Emergent AEs — 4 Participants
N/A N=108 Pipeline for Uncoilable or Failed Aneurysms
Intracranial Aneurysm
Primary: Number of Participants With the Occurrence of Major Ipsilateral Stroke or Neurologic Death and Occurrence of Ipsilateral Stroke or Neurologic Death. — 6; 10 Participants…
Phase 3 N=263 Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c (%) (Glycosylated Haemoglobin) — -1.11; -1.13 Percentage (%) of HbA1c — p=0.8426
Phase 4 N=127 Corticolimbic Degeneration and Treatment of Dementia
Dementia
Primary: Rate of Change of Hippocampal Volume Slope — -70.2418748; -88.4738591; -94.0768115; -46.9484805 mm^3/year — p=0.095
Phase 4 N=21 Ultrasound Guided Octreotide LAR Injection in Acromegaly
Acromegaly
Primary: Plasma Octreotide Level After Each Treatment Phase — 885; 1167 pg/mL — p=0.40
Phase 4 N=105 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
Nonalcoholic Steatohepatitis
Primary: Liver Histology (Kleiner's et al Criteria, Hepatology 2005) — 7; 13; 24 Participants
N/A N=88 Treatment of Post-Traumatic Brain Injury (Post-TBI) Fatigue With Light Therapy
Traumatic Brain Injury · Fatigue
Primary: Multidimensional Assessment of Fatigue (MAF) — 33.332; 30.531; 27.993; 24.937 score on a scale
N/A N=47 Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes
Type 2 Diabetes
Primary: Percent Change in Circumferential Strain Before and After Exercise at Baseline, After Vitamin C Infusion, and After Exercise Training — -24; -20; -23; -21 percentage of…
Phase 3 N=38 Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity
Schizophrenia With Impulsivity
Primary: Change From Baseline Brain Activation in the Ventrolateral Prefrontal Cortex (VLPFC) Based on Change From Baseline to Week 6 in fMRI Blood Oxygen-level Dependent (BOLD)…
N/A N=36 Texture Analysis for Postmenopausal Osteoporosis
Osteoporosis · Osteopenia
Primary: Changes in Lumbar Spine BMD +/- Treatment With Alendronate — 5.28; -1.48 Percent Change
N/A N=19 The Effects Upon the Bladder of Transcutaneous Tibial Nerve Stimulation in Acute Traumatic Spinal Cord Injury
Spinal Cord Injury · Neurogenic Bladder
Primary: Number of Participants With Infection — 4; 3 Participants
N/A N=28 Antidepressant Mechanisms of Transcranial Magnetic Stimulation
Depression
Primary: Depression Severity Measured by the Hamilton Depression Rating Scale (24-Item) — 18.2 units on a scale
N/A N=50 Safety and Effectiveness of Jetstream Atherectomy System (J-SUPREME)
Peripheral Arterial Disease
Primary: Primary Patency Rate — 19 Participants
Phase 3 N=621 A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
Type 2 Diabetes Mellitus
Primary: Change From Baseline in A1C at Week 26 (Excluding Rescue Approach) — -0.03; -0.73; -0.91 Percent A1C — p=<0.001